Memantine in the treatment and prophylaxis of bipolar II disorder and comorbid fibromyalgia: a case report.
We have recently reported that memantine has a clinically relevant antimanic and long-lasting mood-stabilizing effect in treatment-resistant bipolar disorders, both as augmenting agent and as monotherapy. We have also observed an acute antimanic and sustained mood-stabilizing effect in a small number of patients with bipolar I disorder who had had minimal previous pharmacotherapy. In this article, we report the case of a young woman suffering from bipolar II disorder with associated fibromyalgia, in whom memantine showed an acute antimanic and a long-term prophylactic effect on both bipolar disorder as well as the associated fibromyalgia syndrome.
GIULIA SERRA, DE CHIARA, and ALEXIA E. KOUKOPOULOS: Sapienza University, NeSMOS Department, Sant'Andrea Hospital and Centro Lucio Bini, Rome, Italy; ATHANASIOS KOUKOPOULOS: Centro Lucio Bini, Rome; GINO SERRA: University of Sassari, Italy; KAHN: Columbia University College of Physicians and Surgeons, New York.
Giulia
G
Serra
Lavinia
L
DE Chiara
Alexia Emilia
AE
Koukopoulos
Athanasios
A
Koukopoulos
Gino
G
Serra
David A
DA
Kahn
D001714:Bipolar Disorder / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D039721:Diagnostic and Statistical Manual of Mental Disorders; D015259:Dopamine Agents / Q000008:administration & dosage; D005260:Female; D005356:Fibromyalgia / Q000150:complications / Q000188:drug therapy / Q000523:psychology; D006801:Humans; D008559:Memantine / Q000008:administration & dosage*; D008875:Middle Aged; D059408:Pain Management / Q000379:methods; D011569:Psychiatric Status Rating Scales; D063189:Symptom Assessment / Q000379:methods; D016896:Treatment Outcome
D015259:Dopamine Agents; D008559:Memantine